Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Helius Medical Technologies ( (HSDT) ) is now available.
On September 29, 2025, Helius Medical Technologies announced a corporate name change to Solana Company, reflecting its commitment to the Solana blockchain. The company has entered a non-binding letter of intent with the Solana Foundation, outlining collaboration terms and purchase options for SOL tokens. This move signifies HSDT’s dedication to becoming a key player in the blockchain industry, leveraging its digital asset treasury strategy to accumulate SOL and support Solana’s growth.
The most recent analyst rating on (HSDT) stock is a Hold with a $15.50 price target. To see the full list of analyst forecasts on Helius Medical Technologies stock, see the HSDT Stock Forecast page.
Spark’s Take on HSDT Stock
According to Spark, TipRanks’ AI Analyst, HSDT is a Neutral.
Helius Medical Technologies faces significant financial challenges, with declining revenue and negative profitability being the most critical factors. While technical indicators show some positive momentum, the stock’s valuation is unattractive due to ongoing losses. The overall score reflects the company’s need to improve financial stability and operational efficiency.
To see Spark’s full report on HSDT stock, click here.
More about Helius Medical Technologies
Helius Medical Technologies, Inc. is a leading neurotech company in the medical device field, focusing on neurologic deficits using an orally applied technology platform. Their primary product, the Portable Neuromodulation Stimulator, aims to enhance neuroplasticity and improve the lives of people with neurologic diseases.
Average Trading Volume: 790,066
Technical Sentiment Signal: Strong Sell
Current Market Cap: $14.65M
See more insights into HSDT stock on TipRanks’ Stock Analysis page.